Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2003
03/12/2003EP1044203B1 3'-epimeric k-252a derivatives
03/12/2003EP0923548B1 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht 1a ligands
03/12/2003EP0900198B1 New vitamin d derivatives with carbo- or heterocyclic substituents at c-25, a process for their production, intermediate products and their use for producing medicaments
03/12/2003EP0869783B1 Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof
03/12/2003EP0742716B1 Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
03/12/2003EP0729459B1 Phenyl-alkyl imidazoles as h3-receptor antagonists
03/12/2003CN1402793A Lentiviral triplex DNA, and vectors and recombinant cells contg. same
03/12/2003CN1402737A 6-mercapto-cyclodextrin derivs.: resersal agent for drug-induced neuromuscular block
03/12/2003CN1402733A Angiogenic proteins and uses thereof
03/12/2003CN1402732A Nb heterocyclic 8-modified adenosine derivs.
03/12/2003CN1402729A Polycycloalkylpurines as adenosine receptor antagonists
03/12/2003CN1402727A Bicyclic imidazo-3-yl-amine derivs. which are substd. on sixth ring
03/12/2003CN1402726A Bicyclic imidazo-5-yl-amine derivs.
03/12/2003CN1402721A Benzoimidazole derivs. useful as antiproliferative agents
03/12/2003CN1402720A 2,4-diaminopyrimidine compounds useful as immunosuppressants
03/12/2003CN1402717A Benzothiadiazine derivs., preparation method and pharmaceutical compositions contg. same
03/12/2003CN1402709A 4-pyridinyl-N-acyl-L-phenylalanines
03/12/2003CN1402702A Beta 2-adrenergic receptor agonists
03/12/2003CN1402642A Solutions and methods for inhibition of pain, inflammation and cartilage degradation
03/12/2003CN1402640A Stabilized liquid polypeptide-confg. pharmaceutical compositions
03/12/2003CN1402638A Method of treating substance addiction
03/12/2003CN1402637A Pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
03/12/2003CN1402636A Pharmaceutical formulations contg. zolmitriptan
03/12/2003CN1401780A Method for preparing corydamine by biotransformation and use thereof in preparing analgesic
03/12/2003CN1401643A Process for preparing total jujuboflavone with calmative and hypnosis action
03/12/2003CN1401381A Antidepressant composition and preparing process thereof
03/12/2003CN1401335A Medicine for withdrawal of drug addiction and preparing process thereof
03/12/2003CN1401319A Use of GABA transport protein inhibitor in preparing medicine for treating alcohol habituation and abuse
03/12/2003CN1401317A Use of bismuth subgallate in suppressing formation of nitrogen oxide synthetase
03/12/2003CN1401257A Chewing gum component for eliminating nicotine
03/12/2003CN1102852C Administration media for analygesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compsns. containing such media and drugs
03/12/2003CA2422024A1 Process for the production of chiral compounds
03/11/2003WO2002022578A1 (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
03/11/2003US6531600 Treatment and compounds
03/11/2003US6531511 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
03/11/2003US6531503 Benzofurane derivatives
03/11/2003US6531493 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
03/11/2003US6531492 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
03/11/2003US6531488 Method of treating neurodegenerative diseases
03/11/2003US6531483 Treating psychostimulant abuse, inhibiting action of psychostimulant, inhibiting neurotransmitter re-uptake, treating Parkinson's Disease, treating depression
03/11/2003US6531478 For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders
03/11/2003US6531474 Inhibitors of caspases
03/11/2003US6531471 Morpholinone and morpholine derivatives and uses thereof
03/11/2003US6531469 Substituted 1-(4-piperidyl)-3-(aryl) isothioureas their preparation and their therapeutic application
03/11/2003US6531468 Inhibiting serotonin reuptake in the central nervous system of a mammal
03/11/2003US6531450 Use treating neuropathological situations caused by the aging of the nervous system; MP52, MP121 are growth or/and differentiation factors of the TGF-beta (transforming growth factor) superfamily
03/11/2003US6531288 Methods to identify compounds that affect the expression level of the syntaxin-1 A encoding gene
03/11/2003US6531153 Composition with sustained release of levodopa and carbidopa
03/11/2003CA2421936A1 (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
03/11/2003CA2056793C 5-amino-5,6,7,8-tetrahydroquinolines and related compounds a process for their preparation and their use as medicaments
03/10/2003CA2401358A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/07/2003WO2002020481A2 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
03/07/2003WO2002020472A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/07/2003CA2421835A1 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridines
03/07/2003CA2421781A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/06/2003WO2003019146A2 High throughput screening assays using fatty acid synthetic enzymes
03/06/2003WO2003018836A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease
03/06/2003WO2003018821A2 Compositions and methods for treating neurodegenerative diseases
03/06/2003WO2003018782A2 Differentiation of neural stem cells and therapeutic use theeof
03/06/2003WO2003018758A2 Reagents and methods for smooth muscle therapies
03/06/2003WO2003018756A2 Methods for preparing purified prostaglandin e synthase
03/06/2003WO2003018754A2 Neural regeneration peptide and methods for their use in treatment of brain damage
03/06/2003WO2003018640A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003WO2003018619A2 Antimicrobial and anti-inflammatory peptides
03/06/2003WO2003018595A2 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
03/06/2003WO2003018589A1 Novel 4-aminofuropyrimidines and the use thereof
03/06/2003WO2003018587A1 Helix mimetics and composition and methods related thereto
03/06/2003WO2003018586A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018585A1 Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018580A1 Naphthyridine derivative
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018574A1 Rapamycin dialdehydes
03/06/2003WO2003018573A1 Rapamycin 29-enols
03/06/2003WO2003018566A1 New piperidinyl derivates as modulators of chemokine receptor activity
03/06/2003WO2003018561A1 N-type calcium channel antagonists for the treatment of pain
03/06/2003WO2003018560A1 N-type calcium channel antagonists for the treatment of pain
03/06/2003WO2003018557A1 Hydrazinopeptoids and their uses for treating cancers
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018546A2 Tricyclic pyridin-2-one analogues as ligands for gaba-a receptors
03/06/2003WO2003018543A1 Novel cyclohexyl sulphones
03/06/2003WO2003018538A1 Novel diarylalkene derivatives and novel diarylalkane derivatives
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018071A1 Transdermal therapeutic system (tts) with fentanyl as active ingredient
03/06/2003WO2003018070A1 Stilbene derivatives and their use for binding and imaging amyloid plaques
03/06/2003WO2003018060A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
03/06/2003WO2003018041A1 Method of treating spinal injury and remedy therefor
03/06/2003WO2003018027A1 Use of pregnane-diones or diols as neuropathic analgesic agents
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003018009A1 A combination of quetiapine and zolmitriptan
03/06/2003WO2003018005A1 use of nefiracetam for treating neurodegeneration
03/06/2003WO2003018004A2 Analgetic pyrroline derivatives
03/06/2003WO2003017994A1 Amidine derivatives for treating amyloidosis
03/06/2003WO2003017984A1 A new extended release oral dosage form
03/06/2003WO2003017983A1 A new extended release oral dosage form
03/06/2003WO2003017982A1 A new extended release oral dosage form
03/06/2003WO2003017949A2 Novel synthetic ganglioside derivatives and compositions thereof
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2003017927A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003WO2003017919A2 Composition comprising wenguanguo extracts, methods for preparing same and uses therof
03/06/2003WO2003000240A3 Stable powder inhalation dosage formulation
1 ... 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 ... 1833